An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine
Raman Mitra, Steven A. Greenstein, Laurence M. Epstein
Abstract
The rapid spread of the coronavirus disease 2019 (COVID-19) pandemic owing to a newly identified coronavirus, SARS-CoV-2, originating in Wuhan, China, has resulted in significant morbidity and mortality around the world. Early reports have shown improved clinical outcome and viral clearance with the use of chloroquine and hydroxychloroquine.1,2
Topics & Concepts
HydroxychloroquineMedicineChloroquineAzithromycinCoronavirus disease 2019 (COVID-19)CoronavirusSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)QT intervalPandemic2019-20 coronavirus outbreakProlongationLidocaineVirologyAnesthesiaInternal medicineDiseasePathologyInfectious disease (medical specialty)OutbreakMalariaMicrobiologyBiologyAntibioticsCardiac electrophysiology and arrhythmiasAntibiotics Pharmacokinetics and EfficacyDrug-Induced Ocular Toxicity